Publications des scientifiques de l'IRD

Abdallah F., Henriet E., Suet A., Arar A., Clemencon R., Malinge J. M., Lecellier Gael, Baril P., Pichon C. (2021). miR-21-3p/IL-22 axes are major drivers of psoriasis pathogenesis by modulating keratinocytes proliferation-survival balance and inflammatory response. Cells, 10 (10), p. 2547 [22 p.].

Titre du document
miR-21-3p/IL-22 axes are major drivers of psoriasis pathogenesis by modulating keratinocytes proliferation-survival balance and inflammatory response
Année de publication
2021
Type de document
Article référencé dans le Web of Science WOS:000713178400001
Auteurs
Abdallah F., Henriet E., Suet A., Arar A., Clemencon R., Malinge J. M., Lecellier Gael, Baril P., Pichon C.
Source
Cells, 2021, 10 (10), p. 2547 [22 p.]
Psoriasis is a chronic inflammatory skin disease that is mediated by complex crosstalk between immune cells and keratinocytes (KCs). Emerging studies have showed a specific psoriatic microRNAs signature, in which miR-21 is one of the most upregulated and dynamic miRNAs. In this study, we focused our investigations on the passenger miR-21-3p strand, which is poorly studied in skin and in psoriasis pathogenesis. Here, we showed the upregulation of miR-21-3p in an IMQ-induced psoriasiform mouse model. This upregulation was correlated with IL-22 expression and functionality, both in vitro and in vivo, and it occurred via STAT3 and NF-kappa B signaling. We identified a network of differentially expressed genes involved in abnormal proliferation control and immune regulatory genes implicated in the molecular pathogenesis of psoriasis in response to miR-21-3p overexpression in KCs. These results were confirmed by functional assays that validated the proliferative potential of miR-21-3p. All these findings highlight the importance of miR-21-3p, an underestimated miRNA, in psoriasis and provide novel molecular targets for therapeutic purposes.

Plan de classement
Sciences fondamentales / Techniques d'analyse et de recherche [020] ; Santé : généralités [050]
Localisation
Fonds IRD [F B010083303]
Identifiant IRD
fdi:010083303
Contact